Effects of lipid delivery on insulin resistance in muscle
Intramyocellular Fatty Acid Trafficking in Insulin Resistance States - Effects of Intestinal Delivery of Lipids
This study is testing how different types of fats affect insulin resistance in the muscles of healthy adults to see if it can help us understand issues related to Type 2 diabetes.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 55 Years |
| Sex | All |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Trial ID | NCT03818178 on ClinicalTrials.gov |
What this trial studies
This study investigates how the delivery of different types of lipids affects insulin resistance in muscle tissue among healthy, non-obese adults. Participants will receive either an overnight infusion of palm oil or Intralipid, with a saline control, to assess how these lipids influence fatty acid trafficking and insulin signaling. The study aims to clarify the role of intramyocellular fatty acids in muscle insulin resistance, which is a key factor in conditions like Type 2 diabetes. By measuring changes in muscle fat storage and glucose disposal rates, the research seeks to provide insights into metabolic health.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy, non-obese adults aged 18-65 with a BMI between 18 and 27.
Not a fit: Patients with ischemic heart disease, atherosclerotic valvular disease, or those on medications that alter lipid profiles may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new strategies for managing insulin resistance and improving metabolic health in patients.
How similar studies have performed: While the specific approach of this study is novel, previous research has indicated that lipid profiles can significantly impact insulin sensitivity.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women and Men (Women premenopausal) * BMI 18-27 * Weight stable * Not pregnant/nursing Exclusion Criteria: * Ischemic heart disease * Atherosclerotic valvular disease * Smokers (\> 20 cigarettes per week) * Bilateral oophorectomy * Concomitant use of medications that can alter serum lipid profile (high dose fish oil, statins, niacin, fibrates, thiazolinediones, beta-blockers, atypical antipsychotics) * Lidocaine allergy
Where this trial is running
Rochester, Minnesota
- Mayo Clinic — Rochester, Minnesota, United States (Recruiting)
Study contacts
- Principal investigator: Michael D Jensen, MD — Mayo Clinic
- Study coordinator: Pamela Reich
- Email: Reich.Pamela@mayo.edu
- Phone: 507-255-6062
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.